Sunitinib maleate
- 1 April 2006
- journal article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 5 (4) , 279-280
- https://doi.org/10.1038/nrd2012
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Renal-Cell CarcinomaNew England Journal of Medicine, 2005
- Tyrosine Kinases as Targets for Cancer TherapyNew England Journal of Medicine, 2005
- Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)Journal of Clinical Oncology, 2005
- Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC)Journal of Clinical Oncology, 2005
- AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC)Journal of Clinical Oncology, 2005
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitorsJournal of Clinical Investigation, 2003
- Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine KinaseJournal of Medicinal Chemistry, 2003
- Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571)European Journal Of Cancer, 2002